ClinicalTrials.gg
RecruitingNCT04903223Updated Nov 2, 2026

Liver Adiposity Effects on Pediatric Statin

A Phase 1 interventional study of Rosuvastatin 10mg in Cholesterol; Lipidosis, sponsored by Children's Mercy Hospital Kansas City. Recruiting at 1 site in United States. Open to participants aged 8 Years to 21 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Children's Mercy Hospital Kansas City · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2021; still recruiting 5 years 7 months later.
Updated Nov 2, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
8 Years to 21 Years
Sex
All
01

Study summary

Single center, open-label, prospective investigation to quantify the effects hepatocellular fat has on hepatic statin transport and response in children and adolescents in obese and non-obese children and adolescents 8-21 years of age with normal, wild-type SLCO1B1 c.521TT genotype that are dosed rosuvastatin

02

Conditions studied

  • Cholesterol; Lipidosis

Browse trials for

03

In context

Lipidoses

16 studies on the registry are indexed under Lipidoses; 3 are open to participants now.

Browse Lipidoses studies →

Lead sponsor

Children's Mercy Hospital Kansas City is the lead sponsor of 210 studies on the registry; 20 are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 14 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years to 21 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 8-21 years
  • LDL cholesterol >130mg/dl (>95% percentile)
  • SLCO1B1 c.521TT genotype
  • Provide informed permission-assent(\<18 yrs.) or consent (≥18 yrs.)
  • Fasting overnight (\~8 hrs.)
  • Enrolled in Cardiology Pharmacogenomic Repository

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Non-fasting
  • Non-removable metal in body or MRI unsafe
  • Currently on statin therapy and unwilling to wash out of statin therapy for at least 4 weeks prior to Visit 1 and throughout the duration of the study.
  • Underlying unrepaired congenital or acquired cardiovascular defects or repaired congenital or acquired cardiovascular defects with hemodynamically significant residual disease.
  • History of underlying or laboratory evidence of underlying intestinal, metabolic, , renal disease that can alter rosuvastatin disposition* (absorption, metabolism, distribution, or clearance)
  • Pharmacotherapy that interacts with statins (OATP1B1 inducers/inhibitors) *
  • Inability to swallow a tablet
  • >5x the age-specific for , ALT, total and conjugated
  • Diarrhea in the last 24 hours
  • Anything that would exclude a participant from completing an MRI, such as pacemakers, claustrophobia, or body habitus (e.g., weight greater than 350 lbs.)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • No intervention
    Baseline Mevalonate and MRI Imaging
  • Experimental
    Mevalonate Change After Rosuvastatin

    Drug: Rosuvastatin 10mg

Interventions

06

What researchers measure

Primary outcomes

  1. Evaluate effect of Liver Fat Percentage (on MRI) on AUC

    We expect that increased liver adiposity will be associated with higher systemic statin exposure and thus, place those with higher liver adiposity fraction at increased risk for drug toxicity.

    Time frame: 2 years

  2. Evaluate effect of Liver Fat Percentage (on MRI) on change on plasma mevalonate level

    We expect that increased liver adiposity will be associated with an attenuated mevalonate response to a statin in obese children placing those with increased liver adiposity at risk for treatment failure.

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Apr 2021 (actual). Primary completion is estimated for Oct 2027, 78 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Oct 2026 → Oct 2027 and completion Mar 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2021
First posted
May 26, 2021
StartActual
Apr 1, 2021
Primary completionEst.
Oct 30, 2027was Oct 2026
CompletionEst.
Dec 31, 2027was Mar 2027
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 30, 2026→Oct 30, 2027
Nov 2, 2026
Study completion
Mar 31, 2027→Dec 31, 2027
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Primary completion Oct 30, 2026→Oct 30, 2027
    Study completion Mar 31, 2027→Dec 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04903223
Responsible party
Jon Wagner (Principal Investigator, Children's Mercy Hospital Kansas City) — Principal investigator
First posted
May 26, 2021
Start date
Apr 1, 2021
Primary completion
Oct 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 2, 2026

Study contacts

Jonathan Wagner, DO
Contact
jbwagner@cmh.edu
816-731-7240
Jazzie K Holliday
Contact
jkholliday@cmh.edu
816-302-3500

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rosuvastatin

Start the discussion